Literature DB >> 9223312

Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma.

R J Davis1, F G Barr.   

Abstract

Chromosomal translocations identified in hematopoietic and solid tumors result in deregulated expression of protooncogenes or creation of chimeric proteins with tumorigenic potential. In the pediatric solid tumor alveolar rhabdomyosarcoma, a consistent t(2;13)(q35;q14) or variant t(1;13)(p36;q14) translocation generates PAX3-FKHR or PAX7-FKHR fusion proteins, respectively. In this report, we demonstrate that in addition to functional alterations these translocations are associated with fusion product overexpression. Furthermore, PAX3-FKHR and PAX7-FKHR overexpression occurs by distinct mechanisms. Transcription of PAX3-FKHR is increased relative to wild-type PAX3 by a copy number-independent process. In contrast, PAX7-FKHR overexpression results from fusion gene amplification. Thus, gene-specific mechanisms were selected to overexpress PAX3-FKHR and PAX7-FKHR in alveolar rhabdomyosarcoma, presumably due to differences in regulation between the wild-type loci. We postulate that these overexpression mechanisms ensure a critical level of gene product for the oncogenic effects of these fusions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223312      PMCID: PMC21554          DOI: 10.1073/pnas.94.15.8047

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma.

Authors:  J A Biegel; R S Meek; A H Parmiter; K Conard; B S Emanuel
Journal:  Genes Chromosomes Cancer       Date:  1991-11       Impact factor: 5.006

2.  Structural analysis of a carcinogen-induced genomic rearrangement event.

Authors:  F G Barr; R J Davis; L Eichenfield; B S Emanuel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

3.  The murine paired box gene, Pax7, is expressed specifically during the development of the nervous and muscular system.

Authors:  B Jostes; C Walther; P Gruss
Journal:  Mech Dev       Date:  1990-12       Impact factor: 1.882

4.  Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma.

Authors:  F G Barr; N Galili; J Holick; J A Biegel; G Rovera; B S Emanuel
Journal:  Nat Genet       Date:  1993-02       Impact factor: 38.330

5.  Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins.

Authors:  M Bernasconi; A Remppis; W J Fredericks; F J Rauscher; B W Schäfer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma.

Authors:  D N Shapiro; J E Sublett; B Li; J R Downing; C W Naeve
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

7.  Cytogenetic studies in subgroups of rhabdomyosarcoma.

Authors:  J Whang-Peng; T Knutsen; K Theil; M E Horowitz; T Triche
Journal:  Genes Chromosomes Cancer       Date:  1992-11       Impact factor: 5.006

8.  Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints.

Authors:  J Zucman; O Delattre; C Desmaze; B Plougastel; I Joubert; T Melot; M Peter; P De Jong; G Rouleau; A Aurias
Journal:  Genes Chromosomes Cancer       Date:  1992-11       Impact factor: 5.006

9.  Characterization of the transcription products of glyceraldehyde 3-phosphate-dehydrogenase gene in HeLa cells.

Authors:  C Dani; M Piechaczyk; Y Audigier; S El Sabouty; G Cathala; L Marty; P Fort; J M Blanchard; P Jeanteur
Journal:  Eur J Biochem       Date:  1984-12-03

10.  Pax-3, a novel murine DNA binding protein expressed during early neurogenesis.

Authors:  M D Goulding; G Chalepakis; U Deutsch; J R Erselius; P Gruss
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

View more
  33 in total

1.  Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia
Journal:  Mol Cancer Res       Date:  2010-09-22       Impact factor: 5.852

2.  Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.

Authors:  Aishwarya G Jacob; Dennis O'Brien; Ravi K Singh; Daniel F Comiskey; Robert M Littleton; Fuad Mohammad; Jordan T Gladman; Maria C Widmann; Selvi C Jeyaraj; Cheryl Bolinger; James R Anderson; Donald A Barkauskas; Kathleen Boris-Lawrie; Dawn S Chandler
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

3.  Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.

Authors:  L Krsková; M Mrhalová; D Sumerauer; R Kodet
Journal:  Virchows Arch       Date:  2005-12-20       Impact factor: 4.064

4.  The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain.

Authors:  P Y Lam; J E Sublett; A D Hollenbach; M F Roussel
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

5.  Clinical utility gene card for: Alveolar rhabdomyosarcoma.

Authors:  Zhongxin Yu; Anna Kelsey; Rita Alaggio; David Parham
Journal:  Eur J Hum Genet       Date:  2011-08-10       Impact factor: 4.246

6.  PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.

Authors:  Berkley E Gryder; Marielle E Yohe; Hsien-Chao Chou; Xiaohu Zhang; Joana Marques; Marco Wachtel; Beat Schaefer; Nirmalya Sen; Young Song; Alberto Gualtieri; Silvia Pomella; Rossella Rota; Abigail Cleveland; Xinyu Wen; Sivasish Sindiri; Jun S Wei; Frederic G Barr; Sudipto Das; Thorkell Andresson; Rajarshi Guha; Madhu Lal-Nag; Marc Ferrer; Jack F Shern; Keji Zhao; Craig J Thomas; Javed Khan
Journal:  Cancer Discov       Date:  2017-04-26       Impact factor: 39.397

7.  Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  Fenghai Duan; Lynette M Smith; Donna M Gustafson; Chune Zhang; Mandy J Dunlevy; Julie M Gastier-Foster; Frederic G Barr
Journal:  Genes Chromosomes Cancer       Date:  2012-03-23       Impact factor: 5.006

8.  Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling.

Authors:  Marcin Wysoczynski; Rui Liu; Magda Kucia; Justyna Drukala; Mariusz Z Ratajczak
Journal:  Mol Cancer Res       Date:  2010-05-04       Impact factor: 5.852

9.  Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Aditi S Iyengar; Jacob M Loupe; Andrew D Hollenbach
Journal:  Int J Biochem Cell Biol       Date:  2011-03-31       Impact factor: 5.085

Review 10.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.